Marika Rasschaert1, Christof Vulsteke2,3, Sven De Keersmaeker4, Kathleen Vandenborne4, Stefanie Dias2, Vincent Verschaeve5, Peter Vuylsteke6, Ilse Van Brussel7, Jo Ravelingien7, Peter Van Dam8, Eva Segelov9, Marc Peeters4. 1. Department of Oncology, Multidisciplinary Oncological Center Antwerp, MOCA, University Hospital Antwerp, Wilrijkstraat 10, 2650, Edegem, Belgium. marika.rasschaert@uza.be. 2. Department of Medical Oncology, AZ Maria Middelares, Ghent, Belgium. 3. Department of Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO); Center for Oncological Research (CORE), Antwerp University, Antwerp, Belgium. 4. Department of Oncology, Multidisciplinary Oncological Center Antwerp, MOCA, University Hospital Antwerp, Wilrijkstraat 10, 2650, Edegem, Belgium. 5. Department of Oncology and Hematology, Grand Hôpital de Charleroi (GHDC)-site Notre Dame, Charleroi, Belgium. 6. Medical Oncology, CHU UCL, UCLouvain Site St-Elisabeth's Hospital, Namur, Belgium. 7. Remedus Bvba, Aartselaar, Belgium. 8. Unit of Gynecologic Oncology, Department of Obstetrics & Gynecology, University Hospital Antwerp, Antwerp, Belgium. 9. Department of Oncology, Monash Health and Monash University, Melbourne, Victoria, Australia.
Abstract
BACKGROUND: Technology-based interventions are increasingly being introduced in routine clinical cancer care. There is a need for reliable systems to monitor treatment-related toxicity in a standardized manner. Such electronic tools bridge the gap in providing quality home-based monitoring. METHODS: From July 2017 to December 2017, we performed a multicentered, non-randomized prospective cohort analysis with patients who were receiving routine chemotherapy for various solid tumors, using a web-based patient-reported toxicity registration, management, and intervention system called AMTRA (ambulatory Monitoring of cancer Therapy using an interactive Application) linked to the homecare nursing organization Remedus®. Twelve common toxicities plus pain and two biometrics could be registered daily or more frequently as required. These were processed centrally to generate tailored advice for lesser symptoms or a phone call from a dedicated nurse in case of severe or prolonged toxicity. A compliance tool to monitor oral therapies was incorporated in the system. RESULTS: One hundred sixty-eight patients (92%) were enrolled, with 31,514 registrations analyzed. One hundred eight patients reported severe toxicity (> 1461 registrations), resulting in 102 clinical interventions ranging from self-management advice, supplemental consultations to hospitalizations. Compliance to oral chemotherapy was high using AMTRA with a median of 98.7% (95 confidence interval (CI) [93.5-100.0%]). Seventy-nine percent of patients stated that the availability of AMTRA self-reports was useful in communication with the care provider, while 75% felt more in control while managing their treatment. CONCLUSIONS: The application of an interactive PRO-system in routine symptom management of cancer patients allowed standardized documentation of toxicities and recorded a high compliance with oral treatment. It allows for rapid interaction for toxicities and cancer-related symptoms experienced at home.
BACKGROUND: Technology-based interventions are increasingly being introduced in routine clinical cancer care. There is a need for reliable systems to monitor treatment-related toxicity in a standardized manner. Such electronic tools bridge the gap in providing quality home-based monitoring. METHODS: From July 2017 to December 2017, we performed a multicentered, non-randomized prospective cohort analysis with patients who were receiving routine chemotherapy for various solid tumors, using a web-based patient-reported toxicity registration, management, and intervention system called AMTRA (ambulatory Monitoring of cancer Therapy using an interactive Application) linked to the homecare nursing organization Remedus®. Twelve common toxicities plus pain and two biometrics could be registered daily or more frequently as required. These were processed centrally to generate tailored advice for lesser symptoms or a phone call from a dedicated nurse in case of severe or prolonged toxicity. A compliance tool to monitor oral therapies was incorporated in the system. RESULTS: One hundred sixty-eight patients (92%) were enrolled, with 31,514 registrations analyzed. One hundred eight patients reported severe toxicity (> 1461 registrations), resulting in 102 clinical interventions ranging from self-management advice, supplemental consultations to hospitalizations. Compliance to oral chemotherapy was high using AMTRA with a median of 98.7% (95 confidence interval (CI) [93.5-100.0%]). Seventy-nine percent of patients stated that the availability of AMTRA self-reports was useful in communication with the care provider, while 75% felt more in control while managing their treatment. CONCLUSIONS: The application of an interactive PRO-system in routine symptom management of cancerpatients allowed standardized documentation of toxicities and recorded a high compliance with oral treatment. It allows for rapid interaction for toxicities and cancer-related symptoms experienced at home.
Authors: Jeanne Carter; Nadeem R Abu-Rustum; Sally Saban; Ling Y Chen; Andrew J Vickers; Amy L Tin; Gabriela Billanti; Nicole A Connors; Vance Broach; Carol L Brown; Dennis S Chi; Ginger J Gardner; Deborah J Goldfrank; Elizabeth L Jewell; Mario M Leitao; Kara C Long Roche; Jennifer J Mueller; Yukio Sonoda; Oliver Zivanovic Journal: JCO Clin Cancer Inform Date: 2022-02
Authors: Marc Peeters; Peter van Dam; Marika Anna Rasschaert; Christof Vulsteke; Sven De Keersmaecker; Lieselot Croes; Ilse Van Brussel; Jo Ravelingien; Annelies Janssens; Hans Prenen Journal: ESMO Open Date: 2020-06